Laurie D. Stelzer

2018

In 2018, Laurie D. Stelzer earned a total compensation of $2M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, a 6% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$323,489
Option Awards$575,009
Salary$470,000
Stock Awards$575,018
Other$9,409
Total$1,952,925

Stelzer received $575K in stock awards, accounting for 29% of the total pay in 2018.

Stelzer also received $323.5K in non-equity incentive plan, $575K in option awards, $470K in salary and $9.4K in other compensation.

Rankings

In 2018, Laurie D. Stelzer's compensation ranked 5,876th out of 14,244 executives tracked by ExecPay. In other words, Stelzer earned more than 58.7% of executives.

ClassificationRankingPercentile
All
5,876
out of 14,244
59th
Division
Manufacturing
2,229
out of 5,765
61st
Major group
Chemicals And Allied Products
829
out of 2,128
61st
Industry group
Drugs
692
out of 1,817
62nd
Industry
Biological Products, Except Diagnostic Substances
136
out of 339
60th

Pay ratio

Laurie D. Stelzer's Pay$1,952,925
Median Employee's Pay$199,899
Pay Ratio

10

to 1

In 2018, the annual total compensation of Laurie D. Stelzer was $1,952,925.

The annual total compensation of the median employee at Halozyme Therapeutics was $199,899.

The ratio of Laurie D. Stelzer's pay to the pay of median employee was therefore 10 to one.

Source: SEC filing on March 22, 2019.

Stelzer's colleagues

We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2018.

2018

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2018

Benjamin Hickey

Halozyme Therapeutics

Senior Vice President and Chief Commercial Officer

2018

Harry Leonhardt

Halozyme Therapeutics

General Counsel

2018

Dimitrios Chondros

Halozyme Therapeutics

Chief Medical Officer

News

You may also like